IL-13 x TSLP
VIAL-IL13xTSLP has the potential to break the efficacy ceiling in asthma and atopic dermatitis by combining two validated targets. The molecule leverages half-life extension technology to enable a more durable and convenient treatment option.
Key Data
Based on in vitro and in vivo studies, VIAL-INHBE effectively demonstrates functional potency and target-binding comparable to or better than clinical programs.
Synergistic Effect
- Maximally inhibits CCL17 production as compared to marketed anti-IL13 or anti-TSLP mAbs alone.
Favorable Developability
- Developability, a common issue with bi-specifics especially those that have half-life extension, has been de-risked through extensive molecule optimization and validated through preclinical testing.
